These results demonstrate that treatment of HER2-driven GC with trastuzumab activates a feedback loop leading to AKT/mTOR and ERK/mTOR activation, which promoted cell growth and survival, thereby decreasing trastuzumab inhibitor efficacy. The gene discussed is AKT1; the disease is gastric cancer.